Justice, Jamie N.
Pajewski, Nicholas M.
Espeland, Mark A.
Brubaker, Peter
Houston, Denise K.
Marcovina, Santica
Nicklas, Barbara J.
Kritchevsky, Stephen B.
Kitzman, Dalane W.
Funding for this research was provided by:
National Institute on Aging (P30 AG21332, U24AG059624, K01 AG059837, R01 AG020583, R01 AG18915, R01 AG04555)
National Heart, Lung, and Blood Institute (R01 HL093713)
Article History
Received: 23 September 2021
Accepted: 22 December 2021
First Online: 10 January 2022
Declarations
:
: The authors declare no competing interests.
: The SECRET trial was conducted at Wake Forest School of Medicine from February 2009 through November 2014, which was approved by the Institutional Review Board, and registered (NCT00959660).
: All trial participants provided written informed consent.
: All authors consent to publication in GeroScience.NYHA HF Class: New York Heart Association Heart Failure class. Fat mass as total percent body fat from DEXA. IL-6: interleukin-6 (pg/mL). TNFaR1: tumor necrosis factor-receptor 1 (pg/mL). GDF-15: growth differentiating factor-15 (pg/mL). Cystatin C (mg/L). NT-proBNP: N-terminal-pro-natriuretic peptide (pM).<i>IL-6</i>, interleukin-6 (pgmL). <i>TNFaR1</i>, tumor necrosis factor-receptor 1 (pgmL). <i>GDF-15</i>, growth differentiating factor-15 (pgmL). Cystatin C (mgL). <i>NT-proBNP</i>, N-terminal-pro-natriuretic peptide (pM).